NKNijat Khanmammadov

Nijat Khanmammadov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nijat Khanmammadov has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strangulated Inguinal Hernia Caused by Obstructive Sigmoid Colon Carcinoma: A Case Report

    by Elchin Alizade, Elshan Gadimov, Heyder Abbasov, Nijat Khanmammadov, Savalan Karim

    Inguinal hernias are common in the general population and typically contain omentum or small bowel. However, there have also been reports of unusual contents within the hernia sac. We present a rare case of a strangulated left inguinal hernia containing an obstructing sigmoid colon carcinoma. Case Presentation: . A 69- year-old male presented with a several-day history of abdominal pain, distension, vomiting, and bilateral groin swelling. Physical examination revealed a tense abdomen and bilateral inguinal hernias, with the left side being non-reducible. An abdominal CT scan demonstrated herniation of the sigmoid colon into the left inguinal canal, marked colonic dilatation, and air-fluid levels. Emergency surgery was performed through a left inguinal incision, revealing a strangulated segment of the sigmoid colon with a completely obstructing intraluminal mass. To ensure oncologic adequacy, a laparotomy and Hartmann’s procedure were carried out. Due to contamination, the posterior wall of the inguinal canal was repaired without the use of mesh. The patient was discharged on postoperative day 7

  • Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer

    by Nijat Khanmammadov, Izzet Dogan, Necla S. Okay, Bayarmaa Khishigsuren, Abdulmunir Azizy, Pinar Saip, Khayal Gasimli, Adnan Aydiner

    Article: Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer - Minerva Obstetrics and Gynecology 2024 Jun 04 - Minerva Medica - Journals

  • Open Access

    The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data

    by Nijat Khanmammadov, Ferhat Ferhatoglu, Nail Paksoy, İzZet Dogan, Bayarmaa Khishigsuren, Nihan Nizam, Pinar Saip, Adnan Aydiner

    Kaposi sarcoma (KS) is a rare angioproliferative malignancy linked to human herpesvirus 8 infection. While systemic therapy is often unnecessary for classic and iatrogenic KS, advanced cases may require chemotherapy. This study aims to evaluate the efficacy and safety of weekly paclitaxel or oral etoposide as second-line treatments for classical and iatrogenic Kaposi sarcoma. We retrospectively analyzed clinicopathological characteristics and treatment outcomes of 32 patients diagnosed with classical and iatrogenic KS at a tertiary cancer center between December 2000 and November 2022. Patients received oral etoposide (50 mg every 3 weeks for 10 days) or weekly paclitaxel (80 mg/m²). The cohort comprised 23 males (71.9%) and 9 females (28.1%), with a mean age of 63 years. Most patients (87.5%) had classical KS, while 12.5% had iatrogenic KS. The objective response rate (ORR) was 75%, with a disease control rate (DCR) of 87.5%. Median progression-free survival (PFS) was 32.1 months, and median overall survival (OS) was 110.2 months. No significant differences in PFS (P = .633) and OS (P = .456) were observed between paclitaxel and etoposide treatments. The treatment regimen was generally well tolerated. Severe hematological toxicities were less frequent, with febrile neutropenia in 1 patient (3.1%), while severe non-hematological side effects included neuropathy in 2 patients (6.2%). Two patients (6.2%) were hospitalized due to complications, with no treatment-related deaths. Weekly paclitaxel and oral etoposide regimens are effective and well-tolerated second-line treatments for classical and iatrogenic Kaposi sarcoma. Given the high ORR and DCR, these therapies represent viable options for patients who progress after initial treatment. Further studies with larger patient populations are needed to confirm these findings.


  • Open Access

    Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine

    by Nijat Khanmammadov, Izzet Doğan, Bayarmaa Khishigsuren, Abdulmunir Azizy, Pinar Saip, Adnan Aydiner

    Data regarding the use of rechallenge trastuzumab (RTmab)-based therapies in the management of heavily pretreated patients with HER2-positive breast cancer (BC) in the literature are limited. This study aimed to evaluate the efficacy of trastuzumab-based therapy in patients who experienced disease progression after receiving lapatinib plus capecitabine (LC). In this retrospective study, the data of thirty three HER2 positive metastatic BC patients who progressed after LC treatment and subsequently received trastuzumab-based treatment were evaluated. Trastuzumab was administered at an initial loading dose of 8 mg/kg followed by a maintenance dose of 6 mg/kg every 21 days. The average age of patients is 47 years (range 25–72 years). The predominant histopathological subtype was invasive ductal carcinoma, which was observed in 23 (70%) patients. Estrogen receptor (ER) positivity was also noted in 16 (48%) patients. All patients had received palliative trastuzumab plus chemotherapy (Cht) before the lapatinib. In conjunction with trastuzumab-based therapy, vinorelbine was administered to 14 (42%) patients, paclitaxel to 12 (36%), and other chemotherapeutic agents to 4 (12%). For all patients, the objective response and disease control rates were 27% and 69%, respectively. Furthermore, the median progression-free survival (PFS) was 8.8 months (95% confidence interval [CI]: 6.6–11), and the median overall survival was 20 months (95% CI: 15.1–25.8). There were no statistically significant differences in PFS rates based on several factors, including age, ER status, denovo metastasis, brain metastasis, perioperative Cht, pre-Rtmab hormone therapy, and which Cht was used along with Rtmab (P > .05). Mild to moderate adverse events were observed in 17 (52%) patients, whereas only 4 (12%) patients had Grade 3 to 4 toxicity. This study demonstrated that RTmab-based therapy is effective in patients who progressed after LC. These findings contribute to the literature by suggesting that RTmab is a viable treatment option for patients with HER2-positive metastatic BC.


  • Efficacy of Bevacizumab-Based Terapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data

    by Nijat Khanmammadov

    ÖZET Amaç: Bu çalışmanın amacı metastatik serviks kanseri (SK) tanısı konulan hastalarda bevacizumab (BEV ) bazlı tedavilerin güvenliğini ve etkinliğini, gerçek yaşam verileri baz alınarak değerlendirmektir. Gereçler ve Yöntem: Bu çalışma, retrospektif gözlemsel bir analiz içermektedir. Çalışmaya Ocak 2012-Aralık 2022 tarihleri arasında Tıbbi Onkoloji bölümünde BEV tedavisi alan metastatik SK tanılı hastalar dahil edilmiştir. Bulgular: Bu çalışmaya ortalama yaşı 51 (medyan: 21-78) ve tedavi sonrası ortalama takip süresi 16,6 ay olan 40 hasta dahil edildi. Yaygın metastatik bölgeler arasında %72,5 (n=29) lenf nodu, %55 (n=22) periton, %35 (n=14) akciğer, %22,5 (n=9) karaciğer ve %15 (n=6) kemik yer almaktadır. Tedavi yanıtlarına ilişkin olarak hastaların %12,5'inde (n = 5) tam yanıt , %45'inde (n = 18) kısmi yanıt , %17,5'inde (n = 7) stabil yanıt, %25'inde ise (n = 10) progresyon saptandı. Medyan progresyonsuz sağkalım 8,5 ay (%(95% CI: 6.838 – 10.295) ve genel sağkalım ise 16,3 ay (95% CI: 11.305 – 21.362) olarak bulundu. Kemik metastazı varlığı (p=0,024) ve obezite (p=0,020) sağkalım sonuçlarını etkileyen istatistiksel olarak anlamlı faktörlerdir. Yaş, patoloji alt grupları, metastatik bölge sayısı, tümör gradı, başlangıç evresi, tedavi öncesi cerrahi ve radyoterapi, ve BEV ile eşzamanlı uygulanan sitotoksik ajan türü gibi çeşitli faktörlere bağlı olarak genel sağkalım sonuçlarında istatistiksel olarak anlamlı bir fark bulunmadı (p > 0.05). Sonuç: Metastatik SK tanılı hastaların prognozu kötüdür. BEV'in kemoterapi ajanlarıyla kombinasyonları bu hasta grubunun tedavisinde etkili ve güvenlidir. Anahtar Kelimeler: Serviks kanseri, bevacizumab, kemoterapi

  • Open Access

    Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study

    by Ferhat Ferhatoglu, Nail Paksoy, Nijat Khanmammadov, Anil Yildiz, Melin Aydan Ahmed, Zafer Gülbas, Mert Basaran

    Despite having a higher mortality risk than conventional chemotherapeutics, high-dose chemotherapy (HDCT) has the potential to be curative in relapsed/refractory germ-cell tumors. Therefore, selecting the best patient group for this treatment is critical. This study aimed to determine the factors that affect survival in our relapsed/refractory GCT cohort who received HDCT and autologous stem-cell transplantation. Between September 2010 and 2020, we included in the study 44 relapsed/refractory male patients with GCT treated with HDCT plus autologous stem-cell transplantation. The patients’ demographic features, clinical characteristics, and treatment outcomes were evaluated. Statistical analyses were performed to identify risk factors associated with survival. The median age of all cohorts was 28 years. Thirty-six patients had nonseminomatous tumors, and 8 patients had seminomatous tumors. The most common primary tumor sites were the gonads (75%), followed by the mediastinum (15.9%) and the retroperitoneum (9.1%). After HDCT, 11 patients had a complete response, 12 patients had a partial response, and 17 patients had a progressive disease, respectively. About 23 patients (52.3%) experienced at least 1 treatment-related grade 3 to 4 nonhematological toxicity. About 4 patients (10%) died due to HDCT-related toxicity. The total group’s median progression-free survival (PFS) was 7 months, and the median overall survival (OS) was 14.9 months. Primary tumor site (hazard ratio [HR]: 1.84; P = .028), type of HDCT regimen (HR: 0.35; P = .010), and best response to HDCT (HR: 11.0; P < .0001) were independent prognostic risk factors for PFS. The only independent prognostic risk factor associated with OS was the best response to HDCT (HR: 6.62; P = .001). The results of the study promise the best response to HDCT as a primary measure for predicting survival in relapsed/refractory GCT. In contrast, primary mediastinal GCT is not a good candidate for HDCT. Furthermore, a carboplatin–etoposide regimen in combination with cyclophosphamide and paclitaxel may improve PFS.


  • Open Access

    Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer

    by Ni̇jAt Khanmammadov, İzzet Doğan, Necla Simay Okay, Abdulmunir Azizy, Pinar Saip, Adnan Aydiner

    Among all gynecological malignancies, ovarian cancer is the predominant cause of mortality. Hence, various chemotherapy protocols have been established for managing metastatic ovarian cancer cases. The present study aimed to assess and compare the efficacy of dual chemotherapy regimens plus bevacizumab in patients diagnosed with recurrent platinum-sensitive epithelial ovarian cancer. This was a retrospective observational study. Data on the clinical, pathological, radiological, and treatment characteristics of the patients were recorded. Survival analyses were performed using the Kaplan–Meier method. Moreover, multivariate Cox regression analysis was conducted. Data of a total of 198 patients with a median follow-up duration of 18.7 months after bevacizumab treatment were analyzed. Serous carcinoma was found to be the most common pathological subtype in the analyzed patients, accounting for 85.8% of all cases. In total, 46.5% (n = 92), 38.4% (n = 76) and 15.2% (n = 30) patients had received gemcitabine plus carboplatin, paclitaxel plus carboplatin (PC), and gemcitabine plus cisplatin combined with bevacizumab, respectively. The complete response rate was 18.7%, partial response rate was 56.1%, stable disease rate was 6.6%, and progressive disease rate was 18.7%. The patients received bevacizumab treatment at a median of 9 cycles and doublet chemotherapy at a median of 7 cycles. The median progression-free survival was 11.9 (95% CI: 9.2–14.5) months, and the median overall survival (OS) was 24.7 (95% CI: 19.9–29.4) months. The results showed that a history of surgery prior to bevacizumab treatment was a significant factor affecting OS (P = .006). Patients who had received gemcitabine plus carboplatin with bevacizumab (28 months) had significantly better OS than patients who had received paclitaxel plus carboplatin (20.1 months) and gemcitabine plus cisplatin (17 months) (P = .009). Doublet chemotherapy regimens plus bevacizumab are safe and effective against recurrent platinum-sensitive epithelial ovarian cancer. Gemcitabine plus carboplatin with bevacizumab was superior to other treatment regimens in terms of OS outcomes.


  • Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or -Allergic Metastatic Ovarian Cancer

    by Nijat Khanmammadov, İzzet Doğan, Necla Simay Okay, Anıl YILDIZ, Bayarma Khishigsuren, Abdulmunir Azizy, Pinar Saip, Adnan Aydiner

  • Open Access

    Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center

    by Nij̇aT Khanmammadov, Nail Paksoy, İzZet DoğaN, Ferhat FerhatoğlU, Pinar Saip, Adnan Aydiner

    Kaposi sarcoma is a malignant angioproliferative disease, and human herpesvirus-8 plays a major role in its etiology. Iatrogenic Kaposi sarcoma (IKS) can occur in patients undergoing immunosuppressive therapy. The treatment strategy for patients with IKS is immunosuppressive therapy modification. However, it is unclear which chemotherapy drug is the most effective and safe in the treatment of IKS. Therefore, we investigated the efficacy and safety of systemic treatment in patients with IKS at our tertiary cancer center. This cross-sectional retrospective study analyzed the clinical data of 22 patients diagnosed with IKS between January 2000 and January 2020. The patients were divided into the following 2 groups according to the transplantation status: organ transplant recipient (OTR) group and non-organ transplant recipient (non-OTR) group. Of the 22 patients, 12 were included in the OTR group and 10 were included in the non-OTR group. The median patient age at diagnosis was 52.1 years in the OTR group and 68.1 years in the non-OTR group. The median overall survival (OS) was 65.4 months in the OTR group, while the median OS was not reached in the non-OTR group. There was no statistically significant difference in OS between the 2 groups (P = .45). The 5-year OS rate among all patients was 54%. In the OTR group, the objective response rate and disease control rate were 50% and 83%, respectively, and in the non-OTR group, the objective response rate and disease control rate were 60% and 90%, respectively. Chemotherapy was well tolerated in both groups. Hematological toxicities were the main dose-limiting adverse events. Grade III/IV leucopenia and neutropenia were observed in 5 and 4 patients, respectively; however, no patient experienced febrile neutropenia. No chemotherapy-related death occurred. Systemic chemotherapy is an effective treatment and can be considered for disease control in patients with an aggressive disease course, who do not experience regression with immunosuppressive therapy modification.


  • Open Access

    Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

    by Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner

    The purpose of the study was to assess the prognosis of HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression and investigate the predictors of complete response. HER2-positive metastatic breast cancer patients who received long-term trastuzumab were included in the study. Predictors of complete response were analyzed with binary regression analysis. The prognosis of patients who had their trastuzumab-based treatment terminated was assessed. Eighty patients were involved in the study. The patients were received with trastuzumab for a median of 62 months (12–191). A complete response was observed in 60 (75%) patients. The median duration to development of complete response was found as 14.8 months (2.4–55). In logistic regression analysis: using endocrine therapy with trastuzumab (p = 0.04), menopausal status (p = 0.03), and the number of metastatic sites (p = 0.01) were found to be statistically significant factors for a complete response. Trastuzumab-based therapy of fifteen patients was terminated, six (40%) patients continued to receive an aromatase inhibitor, and nine (60%) patients were followed up without treatment. After termination of trastuzumab, at a median follow-up of 32 months (11–66), recurrence was detected in two (13.3%) patients. We detected that menopausal status, the number of metastatic sites, and using endocrine therapy with trastuzumab were predictors of complete response in HER2-positive metastatic breast cancer patients who received long-term trastuzumab-based therapy. We observed that HER2-positive metastatic breast cancer patients may be completely cured with trastuzumab-based therapy. There are no defined criteria for termination of trastuzumab treatment in this selected patient group. It is necessary to confirm our data with multicenter studies involving a large number of patients.